Nov 21, 2022

Featuring a slide presentation and related discussion from Professor Arndt Vogel, including the following topics:

• Advances in first-line treatment for patients with advanced hepatocellular carcinoma (HCC) (0:00)
• Outcomes of Phase III clinical trials evaluating single-agent immunotherapy as initial treatment for advanced HCC (4:19)
• Immune checkpoint inhibitors as second-line treatment for recurrent HCC (6:03)
• Combination therapy as initial treatment for advanced HCC (8:05)
• Sequencing therapies for advanced HCC (13:20)
• Future directions in caring for patients with advanced HCC (22:43)

CME information and select publications